Search clinical trials for: Toripalimab (JS001 )

Total 446 results

Nanfang Hospital of Southern Medical University
Shanghai Junshi Bioscience Co., Ltd.

Recruiting

Neoadjuvant Immunotherapy and Chemotherapy for Locally Advanced Esophagogastric Junction and Gastric Cancer Trial (NICE)

Gastric Cancer | Stomach Neoplasm

China
Air Force Military Medical University, China

Recruiting

GNT Induction Treatment in Locally Advanced NPC

Nasopharyngeal Carcinoma

China
Coherus Biosciences, Inc.
Merck Sharp & Dohme LLC

Recruiting

Study of CHS-388 (Formerly Known as SRF388) in Patients With Advanced Solid Tumors

Clear Cell Renal Cell Carcinoma | Hepatocellular Carcinoma | Advanced Solid Tumor | Non-small Cell Lung Cancer

Korea, Republic of, United States, Singapore
RenJi Hospital

Not yet recruiting

Tripletrumab Combined With Oxaliplatin and Teggio (SOX) in First-line Treatment of Gastric and Gastroesophageal Junction Adenocarcinoma

Gastric Cancer
Polish Lymphoma Research Group
AstraZeneca

Active, not recruiting

Acalabrutinib in CLL and MCL Patients Subjected to Allogeneic Hematopoietic Stem Cell Transplantation (alloSCT) (ACALLO)

Mantle Cell Lymphoma | Chronic Lymphocytic Leukemia | Adverse Event | Chronic Graft-versus-host-disease | Response Rate

Poland
Shanghai Pulmonary Hospital, Shanghai, China

Not yet recruiting

Neoadjuvant Toripalimab Combined With Chemotherapy in the Treatment of Malignant Pleural Mesothelioma

Malignant Pleural Mesothelioma
Dai, Guanghai

Unknown

Toripalimab Combined With S1 and Albumin Paclitaxel in Patients With Advanced Biliary Tract Cancer

Advanced Biliary Tract Cancer

China
Sun Yat-sen University

Recruiting

HAIC Combined With Lenvatinib and PD-1 Inhibitor in Infiltrative Hepatocellular Carcinoma

Hepatocellular Carcinoma | PD-1 Inhibitor | Lenvatinib | Hepatic Arterial Infusion Chemotherapy

China
Fudan University

Not yet recruiting

CAPOX and PD-1 Antibody Combined With or Without Radiotherapy for MSS Locally Advanced Rectal Cancer (TORCH-iTNT)

Neoadjuvant Therapy | Locally Advanced Rectal Cancer

China
Sun Yat-sen University
Second Affiliated Hospital of Guangzhou Medical University

Not yet recruiting

HAIC Combined With Bevacizumab and Toripalimab for Advanced Hepatocellular Carcinama

Liver Neoplasms | Hepatocellular Carcinoma | Bevacizumab | Toripalimab | Oxaliplatin
The Affiliated Nanjing Drum Tower Hospital of Nanjing...
The First Affiliated Hospital with Nanjing Medical University; Fudan University and other collaborators

Not yet recruiting

AG Combined With Immunotherapy and SBRT in Patients With Potentially Resectable Pancreatic Cancer

Pancreatic Carcinoma

China
Ruijin Hospital

Recruiting

Combination Therapy for First Line Treatment of Advanced Cervical Cancer

Advanced Cervical Cancer

China
Shanghai Zhongshan Hospital

Active, not recruiting

Two-cohort Study of Toripalimab(PD1)+Lenvatnib, or Gemox+Lenvatinib in Advanced Intrahepatic Cholangiocarcinoma

Cholangiocarcinoma, Intrahepatic

China
Peking University

Completed

HAIC With Oxaliplatin, 5-FU and Bevacizumab Plus Intravenous Toripalimab for Advanced BTC

Advanced Biliary Tract Cancer

China
Henan Cancer Hospital

Recruiting

Neoadjuvant Toripalimab in Combination With Gemcitabine Therapy in Cisplatin Ineligible Local Advanved Bladder Cancer

Bladder Cancer | Urothelial Carcinoma

China
Peking University Cancer Hospital & Institute

Active, not recruiting

Clinical Study to Evaluate OrienX010 in Combination With Toripalimab as Neoadjuvant Treatment in Advanced Melanoma

Melanoma

China
Johnpro Biotech, Inc.

Recruiting

Phase II/III Trial of CCRT With or Without JP001 for Newly Diagnosed GBM

Glioblastoma

Taiwan
Sun Yat-sen University

Not yet recruiting

TIP Regimen Combined With Triplizumab Neoadjuvant Therapy for Locally Advanced Penile Cancer

Penile Cancer
Beni-Suef University

Not yet recruiting

The Effect of Myo-inositol, Somatropin, and DHEA on Poor Ovarian Responders

Poor Responders

Egypt
XIANG YANQUN

Recruiting

PD-1 Combined With Intensity Modulated Radiation Therapy in the Treatment of Intermediate-risk Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma | T2-3N0 or T1-2N1 | EBV-DNA≤4000 Copy/ml

China
Zhejiang Cancer Hospital

Recruiting

Toripalimab Combined With Apatinib Mesylate for the Treatment of Gastric Adenocarcinoma in a Prospective Randomized Multicenter Phase II Clinical Study

Gastric Adenocarcinoma

China
Fudan University

Recruiting

Short-course Radiotherapy Combined With CapeOx and PD-1 Inhibitor After Local Excision for High-risk Early Rectal Cancer (TORCH-LE)

Rectal Cancer

China
Chongqing University Cancer Hospital

Recruiting

Niraparib Combined With Brivanib or Toripalimab in Patients With Cervical Cancer (CQGOG0101)

Cervical Cancer

China
Eucure (Beijing) Biopharma Co., Ltd

Active, not recruiting

A Study to Assess YH003 in Combination With Toripalimab(Anti-PD-1 mAb) Injection in Patients With Cancers

Melanoma | Pancreatic Ductal Adenocarcinoma

United States, Australia
Hao Long

Active, not recruiting

Neoadjuvant Toripalimab Plus Platinum-based Doublet for Stage III Non-small Cell Lung Cancer (NeoTAP01)

Non Small Cell Lung Cancer

China
Zogenix, Inc.

Completed

Long-Term Study of Hydrocodone Bitartrate Controlled-release Capsules in Subjects With Chronic Pain

Chronic Pain

United States
Sun Yat-sen University

Recruiting

Surufatinib Combined With Chemotherapy Plus Toripalimab or Not in the Treatment of Small Cell Lung Cancer

Small Cell Lung Carcinoma

China
Mian XI

Completed

Combination of Toripalimab and Chemoradiotherapy in Esophageal Cancer

Unresectable Esophageal Cancer

China
Fujian Cancer Hospital

Not yet recruiting

PARP Inhibitor CVL218 in Combination Therapy for Patients With Advanced Solid Tumors

Advanced Solid Tumor
Sun Yat-sen University
Second Affiliated Hospital of Guangzhou Medical University

Completed

Lenvatinib Combined Anti-PD1 Antibody for the Advanced Hepatocellular Carcinoma

Liver Diseases | Hepatocellular Carcinoma | Anti-PD1 Antibody

China
Shanghai Junshi Bioscience Co., Ltd.

Unknown

Safety, Tolerability and Pharmacokinetics of a Recombinant Humanized mAb Specific to B-and T-Lymphocyte Attenuator (BTLA) for Injection in Subjects With Advanced Malignancies

Advanced Solid Tumor

China
Fudan University

Recruiting

The Combination of Immunotherapy and Neoadjuvant Short-course Radiotherapy in Early Rectal Cancer (TORCH-E） (TORCH-E)

Early Low Rectal Cancer

China
Li Zhang, MD

Recruiting

Surufatinib Combined With Toripalimab and Chemotherapy in the Treatment of Non-Small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung

China
Fudan University

Recruiting

Short-course Radiotherapy Based TNT Combined With PD-1 Inhibitor for Locally Advanced Rectal Cancer (TORCH)

Locally Advanced Rectal Cancer

China
Second Affiliated Hospital, School of Medicine,...

Completed

ICIs Neoadjuvant Therapy in Resectable Non-Small-Cell Lung Cancer

High-Risk Resectable NSCLC

China
Wei Ren

Recruiting

Combination of Toripalimab and Neoadjuvant Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma

China
IgNova GmbH
Klinar CRO; Scope International AG; CenTrial GmbH; Pharmasolutions4U; idv Data Analysis...

Completed

Efficacy and Safety of IGN-ES001 in Chronic Widespread Pain With or Without Fibromyalgia

Chronic Widespread Pain | Fibromyalgia

Turkey
Fudan University

Recruiting

Induction Chemotherapy and Toripalimab for Larynx Preservation in Resectable Laryngeal/Hypopharyngeal Carcinoma (INSIGHT)

Laryngeal Cancer | Laryngeal Neoplasms | Hypopharynx Cancer

China
China Medical University, China

Recruiting

Clinical Study of Nab-paclitaxel Combined With Toripalimab in Local Advanced or Metastatic G/GEJ Carcinoma

Gastric Carcinoma

China
Sun Yat-sen University

Active, not recruiting

Toripalimab and Gemcitabine in Recurrent or Metastatic Nasopharyngeal Carcinoma.

Nasopharyngeal Carcinoma | Chemotherapy Effect | Immunotherapy | Recurrent Nasopharyngeal Carcinoma | Metastatic Nasopharyngeal Carcinoma

China
Peking Union Medical College Hospital
Henan Cancer Hospital; Shengjing Hospital; Sun Yat-Sen Memorial Hospital of Sun... and other collaborators

Not yet recruiting

Toripalimab Plus Actinomycin-D as Fist-Line Treatment for GTN With FIGO Score 7 (TA7)

Gestational Trophoblastic Neoplasia

China
Jianhua Fu

Unknown

Combination of Toripalimab and Neoadjuvant Chemoradiotherapy in Esophageal Cancer

Resectable Esophageal Cancer | Esophageal Squamous Cell Carcinoma by AJCC V8 Stage

China
Xuhua Duan

Recruiting

An Observational Real World Study on the Efficacy and Safety of Toripalimab Injection Combined With TACE in the Treatment of Extrahepatic Cholangiocarcinoma

Extrahepatic Cholangiocarcinoma

China
Peking University
CARsgen Therapeutics Co., Ltd.

Completed

Chimeric Antigen Receptor T Cells Targeting claudin18.2 in Solid Tumors.

Advanced Solid Tumor

China
Sun Yat-sen University

Active, not recruiting

PD1 Antibody Toripalimab and Chemoradiotherapy for dMMR/MSI-H Locally Advanced Colorectal Cancer

DMMR Colorectal Cancer | MSI-H Colorectal Cancer | Locally Advanced Colorectal Cancer

China
Xiangya Hospital of Central South University

Unknown

A Personalized NeoAntigen Cancer Vaccine Combined With Anti-PD-1 in Melanoma

Melanoma (Skin)

China
China Medical University, China

Not yet recruiting

Anti-PD-1 Antibody Combined With Autologous DC and NK Cells in the Treatment of Digestive Carcinoma

PD-1 Antibody | Gastrointestinal Tumours | DC-Cell | NK-Cell
Peking Union Medical College Hospital

Recruiting

Regorafenib Combined With PD-1 Inhibitor Therapy for Second-line Treatment of Hepatocellular Carcinoma

Hepatocellular Carcinoma | PD-1 Inhibitor | Regorafenib

China
Shanghai Pulmonary Hospital, Shanghai, China

Not yet recruiting

Adjuvant Toripalimab Plus Chemotherapy for EGFR/ALK Mutation Negative Stage II-IIIB(N2) NSCLC (LungMate-008)

Non Small Cell Lung Cancer
Shanghai Junshi Bioscience Co., Ltd.

Active, not recruiting

Study to Evaluate the Efficacy and Safety of Toripalimab in Combination With Axitinib Versus Sunitinib Monotherapy in Advanced Renal Cell Cancer

Primary Disease: Unresectable or Metastatic Renal Cell Carcinoma Focus of the Study:PFS Assessed by IRC Per RECIST 1.1

China

Search clinical trials for: Toripalimab (JS001 )

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Pakistan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations